Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: Amgen Inc. is conducting a Phase 3 clinical trial titled A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202). The study aims to compare progression-free survival and overall survival in patients treated with sotorasib versus pembrolizumab, both combined with platinum doublet chemotherapy. This study is significant as it targets patients with specific genetic markers, potentially offering more effective treatment options.
Intervention/Treatment: The trial tests two treatments: sotorasib, administered orally, combined with carboplatin and pemetrexed, and pembrolizumab, administered intravenously, also combined with carboplatin and pemetrexed. These combinations aim to improve treatment outcomes for patients with advanced nonsquamous non-small cell lung cancer.
Study Design: This interventional study is randomized with a parallel assignment model and no masking, focusing on treatment as its primary purpose. Participants are randomly assigned to receive either the sotorasib or pembrolizumab combination therapy.
Study Timeline: The study began on November 16, 2023, with recruitment currently ongoing. The primary completion date is yet to be announced, and the last update was submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: This study could significantly impact Amgen’s stock performance and investor sentiment, especially if sotorasib proves more effective than pembrolizumab. Success in this trial may enhance Amgen’s competitive position in the oncology market, particularly against other companies developing treatments for non-small cell lung cancer.
The study is ongoing, with further details available on the ClinicalTrials portal.